Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
Ronald Scott, Basilea's Chief Executive Officer, indicated: "Basilea greatly appreciates Ms. McDaid who built Basilea's human resources department and operations from our founding to a level of industry excellence. Basilea's human resources activities will continue to be in good hands under Ms. Eberhardt, who has been our deputy Head of Global Human Resources for the last seven years. We wish Ms. McDaid all the best in her retirement and much success to Ms. Eberhardt in her new position."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 [email protected] [email protected] |
This press release can be downloaded from www.basilea.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d56fddc3-2502-430d-adbc-9a2ff077d4bd


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Apple Turns 50: From Garage Startup to AI Crossroads
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 



